

Guatemala

| High HIV burden |

Tuberculosis profile

Population 2013

15 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.25 (0.24–0.26)	1.6 (1.6–1.7)
Mortality (HIV+TB only)	0.41 (0.34–0.49)	2.6 (2.2–3.2)
Prevalence (includes HIV+TB)	17 (8.6–28)	110 (56–183)
Incidence (includes HIV+TB)	9.2 (8.2–10)	60 (53–67)
Incidence (HIV+TB only)	0.91 (0.81–1)	5.9 (5.2–6.6)
Case detection, all forms (%)	36 (32–40)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	3 (1.8–4.6)	26 (20–34)
MDR-TB cases among notified pulmonary TB cases	85 (51–130)	62 (46–79)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	2 849	175
Pulmonary, clinically diagnosed	0	0
Extrapulmonary	287	0

Total new and relapse	3 311
Previously treated, excluding relapses	58
Total cases notified	3 369

Among 2 196 new cases:

41 (2%) cases aged under 15 years; male:female ratio: 1.3

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB	5 (<1%)	126 (54%)	262
Laboratory-confirmed RR-/MDR-TB cases			51
Patients started on MDR-TB treatment			28

TB/HIV 2013	Number	(%)
TB patients with known HIV status	2 703	(80)
HIV-positive TB patients	267	(10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	0	(0)
HIV-positive TB patients on antiretroviral therapy (ART)	242	(91)
HIV-positive people screened for TB		
HIV-positive people provided with IPT	316	

Treatment success rate	(%)
New cases registered in 2012	88
Previously treated cases registered in 2012	71
HIV-positive TB cases, all types, registered in 2012	71
RR-/MDR-TB cases started on second-line treatment in 2011	70
XDR-TB cases started on second-line treatment in 2011	

Laboratories 2013	
Smear (per 100 000 population)	1.7
Culture (per 5 million population)	3.9
Drug susceptibility testing (per 5 million population)	0.3
Sites performing Xpert MTB/RIF	0


Is second-line drug susceptibility testing available? Yes, outside country

Financing TB control 2014	
National TB programme budget (US\$ millions)	<1
% Funded domestically	1454%
% Funded internationally	347%
% Unfunded	<1%

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally
Unfunded